Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00006240
First received: September 11, 2000
Last updated: April 30, 2013
Last verified: November 2002

September 11, 2000
April 30, 2013
October 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00006240 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
A Pilot Study of Phenylbutyrate, Dexamethasone and GM-CSF in Refractory or Relapsed t(8;21) Acute Myeloid Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.

PURPOSE: Phase II trial to study the effectiveness of combining phenylbutyrate, dexamethasone, and sargramostim in treating patients who have refractory or relapsed acute myeloid leukemia.

OBJECTIVES:

  • Determine the objective response (complete hematologic remission induction) of phenylbutyrate, dexamethasone, and sargramostim (GM-CSF) in patients with refractory or relapsed t(8;21) acute myeloid leukemia.
  • Determine the correlation between histone acetylation, differentiation, and apoptosis in bone marrow mononuclear cells with response rate in patients treated with this regimen.
  • Determine the overall survival of patients on this regimen.
  • Determine the correlation between histone acetylation, differentiation, and apoptosis in bone marrow mononuclear cells with pharmacokinetics of this regimen in these patients.
  • Determine the safety and toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive phenylbutyrate IV continuously and sargramostim (GM-CSF) subcutaneously on days 1-7 and 15-21. Patients also receive oral dexamethasone on days 1-4 and 15-18. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity until complete hematologic remission is induced. Patients with stable disease at the end of 1 course receive at least 2 additional courses.

Patients are followed twice a week for 3 months, monthly for 1 year, every three months for the next 4 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 9-24 patients will be accrued for this study in at least 2 years.

Interventional
Phase 2
Primary Purpose: Treatment
Leukemia
  • Biological: sargramostim
  • Drug: dexamethasone
  • Drug: oral sodium phenylbutyrate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
August 2001
Not Provided

DISEASE CHARACTERISTICS:

  • Diagnosis of t(8;21) acute myeloid leukemia (AML)

    • Failed standard induction chemotherapy or stem cell transplantation (SCT) OR
    • Relapsed after standard induction chemotherapy or SCT OR
    • Refused or not a candidate for SCT or matched allogeneic sibling bone marrow transplantation or donor lymphocyte infusion OR
    • Refused of not a candidate for autologous SCT or bone marrow transplantation
  • No CNS leukemia

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • At least 7 days

Hematopoietic:

  • Not specified

Hepatic:

  • AST or ALT no greater than 3 times upper limit of normal (ULN)
  • Bilirubin no greater than 3 times ULN
  • No hepatic disease that would preclude study

Renal:

  • Creatinine no greater than 2 mg/dL
  • Creatinine clearance at least 60 mL/min
  • No renal disease that would preclude study

Cardiovascular:

  • No cardiac disease that would preclude study
  • No New York Heart Association class III or IV heart disease
  • No myocardial infarction within past 8 weeks

Other:

  • No active infection except cystitis
  • Not pregnant or nursing
  • No altered mental status or seizure disorder
  • No other serious disease that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • See Disease Characteristics

Chemotherapy:

  • See Disease Characteristics

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • Not specified

Other:

  • At least 3 weeks since prior investigational antineoplastic drugs
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00006240
CDR0000068165, NHLBI-00-H-0156, NCI-171
Not Provided
Not Provided
National Heart, Lung, and Blood Institute (NHLBI)
Not Provided
Study Chair: Johnson Liu, MD National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI)
November 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP